CARTITUDE-1 Demonstrates Potential Best-in-Class Efficacy; Ide-cel’s CRB-401 Study Updates mDoR Data; Clinical and Manufacturing Updates for bb21217; A Comparison of Tecartus vs Liso-cel in MCL; Day 1 ASH 2020 Highlights

On the first day of ASH 2020, four key clinical updates were presented from BMS / bluebird, JNJ / Legend, and Gilead. Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.